David Ansell to Risk Assessment
This is a "connection" page, showing publications David Ansell has written about Risk Assessment.
Connection Strength
0.336
-
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis. 2018 01; 268:99-107.
Score: 0.120
-
Factors that influence access to the national renal transplant waiting list. Transplantation. 2009 Jul 15; 88(1):96-102.
Score: 0.067
-
UK Renal Registry 11th Annual Report (December 2008): Chapter 7 Survival and causes of death of UK adult patients on renal replacement therapy in 2007: national and centre-specific analyses. Nephron Clin Pract. 2009; 111 Suppl 1:c113-39.
Score: 0.066
-
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice. Atherosclerosis. 2018 04; 271:120-127.
Score: 0.031
-
The racial disparity in breast cancer mortality. J Community Health. 2011 Aug; 36(4):588-96.
Score: 0.019
-
Social deprivation, ethnicity, and access to the deceased donor kidney transplant waiting list in England and Wales. Transplantation. 2010 Aug 15; 90(3):279-85.
Score: 0.018
-
Patient dumping. Status, implications, and policy recommendations. JAMA. 1987 Mar 20; 257(11):1500-2.
Score: 0.014